BMY · Categories · Offerings
BMY - Public offerings
Bristol-Myers Squibb Company (BMY) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for BMY
- Bristol Myers Squibb Prices €5 Billion of Senior Unsecured NotesBristol Myers Squibb (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of €5 billion (collectively, the "Notes"). The Notes will be issued by Bristol Myers Squibb's wholly-owned subsidiary, BMS Ireland Capital Funding Designated Activity Company, in five tranches: (i) €750,000,000 aggregate principal amount of 2.973% Notes due 2030, (ii) €1,150,000,000 aggregate principal amount of 3.363% Notes due 2033, (iii) €1,150,000,000 aggregate principal amount of 3.857% Notes due 2038, (iv) €750,000,000 aggregate principal amount of 4.289% Notes due 2045, and (v) €1,200,000,000 aggregate principal amoun
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsContinued progress enrolling in its VMT-α-NET and VMT01 clinical trialsDisclosed a new internally discovered molecule that targets fibroblast activation protein-αAnnounced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sitesRaised $177.2 million in gross proceeds through various financing transactions and raised an additional $49.5 million subsequent to March 31st under our ATM Agreement. SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today annou
- PureTech Announces Annual Results for Year Ended December 31, 2023Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for Seaport, and the $14 billion acquisition of Karuna by Bristol Myers Squibb Robust balance sheet with PureTech level cash, cash equivalents and short-term investments of $326.0 million3 and consolidated cash, cash equivalents and short-term Investments of $327.1 million4 as of December 31, 2023 As of March 31, 2024, PureTech level cash, cash equivalents and short-term investments were $573.3 million,5 enabling the support of Internal Programs and Founded Entities, future innovations, shareholder re
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsSEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. "We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies," said Thijs Spoor, Perspective Therapeutics' CEO. "We are pleased with our continued momentum into 2024. In March 2024, we acquired a radiopharmaceutical manufacturing facility to suppo
- Bristol Myers Squibb Prices $13 Billion of Senior Unsecured NotesBristol Myers Squibb (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $13 billion (collectively, the "Notes"). The Notes will be issued in nine tranches: (i) $500,000,000 in aggregate principal amount of floating rate notes due 2026, (ii) $1,000,000,000 in aggregate principal amount of 4.950% notes due 2026, (iii) $1,000,000,000 in aggregate principal amount of 4.900% notes due 2027, (iv) $1,750,000,000 in aggregate principal amount of 4.900% notes due 2029, (v) $1,250,000,000 in aggregate principal amount of 5.100% notes due 2031, (vi) $2,500,000,000 in aggregate principal amount of 5.200%
- Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured NotesBristol Myers Squibb (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $4.5 billion (collectively, the "Notes"). The Notes will be issued in four tranches: (i) $1,000,000,000 in aggregate principal amount of 5.750% notes due 2031, (ii) $1,000,000,000 in aggregate principal amount of 5.900% notes due 2033, (iii) $1,250,000,000 in aggregate principal amount of 6.250% notes due 2053, and (iv) $1,250,000,000 in aggregate principal amount of 6.400% notes due 2063. Bristol Myers Squibb expects that the closing of the Offering will occur on November 13, 2023, subject to the satisfaction of customar
- Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura's cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Bristol Myers Squibb (NYSE:BMY) and a term loan facility with access to up to $125 million from Hercules Capital, Inc. (NYSE:HTGC). If the term loan is fully drawn, proceeds from these two transa
- Bristol Myers Squibb Prices $6 Billion of Senior Unsecured NotesBristol-Myers Squibb Company (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $6 billion (collectively, the "Notes"). The Notes will be issued in four tranches: (i) $1,750,000,000 in aggregate principal amount of 2.950% notes due 2032, (ii) $1,250,000,000 in aggregate principal amount of 3.550% notes due 2042, (iii) $2,000,000,000 in aggregate principal amount of 3.700% notes due 2052, and (iv) $1,000,000,000 in aggregate principal amount of 3.900% notes due 2062. Bristol Myers Squibb expects that the closing of the Offering will occur on March 2, 2022, subject to the satisfaction of custom
- TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateCAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. "Over the last few months, we continue to treat cancer patients in our ongoing gavo-cel Phase 1 clinical trial and have observed meaningful clinical benefit in three different treatment-refractory solid tumor indications," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "As we prepare for the phase 2 trial to be launched in